Pharma Reviews: Indian drugmakers' revenue growth in US may cool off to 7-10% over 3 years: ICRA

The domestic market considered to be the safe bet for Indian generic drug makers with favorable macro-economic indicators and predictable ...
Read more: Indian drugmakers' revenue growth in US may cool off to 7-10% over 3 years: ICRA